Injeq raises EUR 1.7M via Invesdor.
The campaign, which was started in May 2017, was funded by 708 investors which oversubscribed 6x the initial target investment of EUR 250k.
Injeq, founded by Kai Kronström (CEO), Jari Hyttinen, Riitta Seppänen-Kaijansinkko and Katja Paassilta, is working for the development of a spinal needle that allows for collecting diagnostic samples of cerebrospinal fluid (CSF) and for administering intrathecal drugs into the CFS e.g. as part of leukemia treatment. The estimated annual market potential in European pediatric hospitals is 51 million euros and the company also intends to expand in the USA.